Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3815 Real-world observational study of somatostatin analogues and rescue medication use for neuroendocrine tumors in Canada

Introduction: Both octreotide long-acting release (OCT-LAR) and lanreotide autogel (LAN-ATG) are available in Canada for the management of neuroendocrine tumors (NETs). Patients can switch between SSAs due to effectiveness, adverse events (AEs), preference or reimbursement. For patients with functional disease, short acting SSAs can be used concomitantly as rescue medication to improve symptom control.

Conference:

Presenting Author:

Authors: Rayson D, Troesch M, Laforty C, Badin M, Liovas A,

Keywords: Neuroendocrine tumor, Somatostatin analogues, Lanreotide, Octreotide, SSA switch,

#3470 Molecular Imaging Tumor Volume of Somatostatin Receptor (MITVSSR) on 68Ga-DOTATATE PET/CT, dosimetry and predictors of overall survival and response in unresectable neuroendocrine neoplasms treated with Peptide Receptor Radionuclide Therapy (PRRT)

Introduction: PRRT delivers targeted radionuclide therapy to Neuroendocrine Neoplasms (NENs) with high SSR expression.

Conference:

Presenting Author:

Authors: Alipour R, Jackson P, Callahan J, Bressel M, Hogg A,

Keywords: PRRT, dosimetry, survival, response,

#2842 Transformation to High Grade 3 (G3) Neuroendocrine Neoplasia (NEN) – Molecular Imaging, Pathologic Features and Patient Outcomes

Introduction: Transformation of lower grade to Grade 3 (G3) NEN potentially impacts prognosis & treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kong G, Callahan J, Prall O, Michael M, Hicks R,

Keywords: Transformation, G3 NEN, PET imaging, mutation, PRRT, prognosis,

#1784 Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)

Introduction: Treatment options for metastatic PCC/PGL and related hypertension (HTN) are limited. Experiences in PRRT suggest favourable disease control, but lack of data on HTN response.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: kong G

Authors: Kong G, Grozinsky-Glasberg S, Callahan J, Hofman M, Meirovitz A,

Keywords: PRRT,

#1391 Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) - A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)

Introduction: Bulky disease from NET is an adverse prognostic factor for response to 177Lu-DOTA-octreotate (LuTate) PRCRT. 90Y-DOTA-octreotate (YTate) has more penetrating particulate emissions.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Kong G, Callahan J, Hofman M, Pattison D, Akhurst T,

Keywords: PRRT, Y-90,